Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent ActivityPRNewsWire • 05/06/21
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose SelectionPRNewsWire • 04/15/21
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in AprilPRNewsWire • 04/13/21
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838PRNewsWire • 03/31/21
Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent ActivityPRNewsWire • 02/26/21
Immunic's IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease StudyBenzinga • 02/18/21
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing CholangitisPRNewsWire • 02/18/21
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 TrialPRNewsWire • 02/17/21
Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25PRNewsWire • 02/11/21
Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to ProceedPRNewsWire • 11/02/20
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 TherapyPRNewsWire • 10/20/20
Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19PRNewsWire • 09/28/20
Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020PRNewsWire • 09/11/20
